Moderna, Inc. - MRNA STOCK NEWS

Moderna, Inc. (Nasdaq: MRNA) announced a new supply agreement with Israel for 2022, allowing Israel to purchase doses of Moderna's COVID-19 vaccine and a variant-specific vaccine pending regulatory approval. This follows two previous agreements totaling 10 million doses. CEO Stéphane Bancel emphasized the significance of this agreement as a milestone for 2022 supply and ongoing clinical trials for variant-specific boosters, which have shown promising preclinical efficacy against COVID-19 variants.

Moderna, Inc. (Nasdaq: MRNA) will host a live conference call on May 6, 2021, at 8:00 a.m. ET to report its Q1 2021 financial results and provide a corporate update. Investors can join by dialing 866-922-5184 (domestic) or 409-937-8950 (international) with conference ID 7487119. The call will also be webcast and archived on Moderna’s investor website for a year. Over the past ten years, Moderna has evolved significantly, developing a diverse portfolio of vaccines and therapeutics, including one of the earliest COVID-19 vaccines, thanks to its advanced mRNA technology.

Moderna (Nasdaq: MRNA) hosted its second annual Vaccines Day, showcasing its mRNA vaccine capabilities. The company revealed new positive interim Phase 1 data for its Respiratory Syncytial Virus (RSV) vaccine candidate (mRNA-1345) and interim Phase 2 data for its cytomegalovirus (CMV) candidate. Moderna aims to leverage its mRNA platform to accelerate vaccine development, addressing the significant gap in available vaccines for many human viruses. The Phase 1 analysis indicates mRNA-1345 is well-tolerated, with no severe adverse events reported, furthering Moderna's innovative vaccine pipeline.

Moderna (Nasdaq: MRNA) released updates on its COVID-19 Vaccine program, highlighting progress in variant-specific booster candidates mRNA-1273.351 and mRNA-1273.211, which show increased neutralizing titers against concerning SARS-CoV-2 variants. Approximately 132 million doses have been delivered globally, with efficacy rates exceeding 90% for all COVID-19 cases and over 95% for severe cases. The company is running multiple studies, including the Phase 2/3 TeenCOVE and KidCOVE studies, while also reporting no association between its vaccine and cerebral venous sinus thrombosis after administering over 64.5 million doses.

Moderna (Nasdaq: MRNA) has announced that David Meline, CFO, and Lavina Talukdar, SVP of Investor Relations, will engage in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. The event will be accessible via a live webcast on Moderna's investor website, with a replay available for 30 days after the presentation.

Over the past decade, Moderna has evolved from an mRNA research stage entity into a leader in mRNA therapeutics and vaccines, currently advancing 24 development programs across various medical fields.

Moderna, Inc. (Nasdaq: MRNA) announced the publication of data in The New England Journal of Medicine showcasing the persistent antibody response achieved by its COVID-19 vaccine six months post-second dose. The study involved 33 participants from a Phase 1 trial, confirming robust antibody levels, aligning with prior findings on natural COVID-19 immunity. Ongoing studies will further evaluate immune responses. Moderna is also advancing its clinical strategy to combat emerging variants and enhance vaccine efficacy as part of its commitment to addressing the pandemic.

Moderna and Catalent have expanded their strategic collaboration, dedicating a new high-speed vial filling line at Catalent's Bloomington facility for the production of the Moderna COVID-19 Vaccine. This expansion follows a successful milestone of 100 million doses achieved in March 2021. The new line will support not only the COVID-19 vaccine but also other investigational programs in Moderna's pipeline until June 2023. Catalent's investment of $50 million will enhance manufacturing capabilities and expedite project timelines.

Moderna (Nasdaq: MRNA) announced FDA authorization allowing the COVID-19 vaccine to be stored at room temperature for 24 hours, an increase from 12 hours, and a punctured vial can now be used for up to 12 hours instead of 6. Additionally, FDA approved new vial presentations for 11 and 15 doses. This change aims to facilitate easier administration and improve vaccine access. The company is committed to optimizing production to enhance vaccine distribution while maintaining quality and safety.

Ximedica has partnered with Moderna (Nasdaq: MRNA) to create a prototype for rapid mobile vaccine and therapeutic manufacturing under DARPA's Nucleic Acids On-Demand World-Wide Program. The collaboration, which spans four years, aims to develop a mobile platform that can quickly diagnose and respond to pathogen threats. Ximedica will receive up to $11 million in funding for this initiative. The project envisions manufacturing units that can produce hundreds of doses in just days, ensuring timely medical responses in remote locations worldwide.